Clinical characteristics and risk factors for prostate cancer with PSA≤20 ng/mL: a multicenter study

Shan Xiongwei; Lü Shidong; Chen Liping; Hu Zhengfei; Gan Shu; Wang Shusheng; Li Yuan

doi:10.13406/j.cnki.cyxb.003301

您当前的位置：

首页 >

文章列表页 >

Clinical characteristics and risk factors for prostate cancer with PSA≤20 ng/mL: a multicenter study

Carcinoma of prostate | 更新时间：2025-10-21

- Clinical characteristics and risk factors for prostate cancer with PSA≤20 ng/mL: a multicenter study
- Journal of Chongqing Medical University Vol. 48, Issue 8, Pages: 931-934(2023)
- 作者机构：
  
  1.广州中医药大学第二附属医院泌尿外科,广州 510105
  2.南方医科大学南方医院泌尿外科,广州 510515
  3.南方医科大学珠江医院特需医疗服务中心,广州 510280
  4.中国人民解放军南部战区总医院泌尿外科,广州 510010
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003301
  CLC： R737.25
- Received：07 April 2023，
  
  Revised：2023-06-21，
  
  Accepted：30 June 2023，
  
  Published：28 August 2023
- 稿件说明：
移动端阅览
单雄威,吕世栋,陈丽萍,等.多中心研究PSA≤20 ng/mL前列腺癌临床特点及危险因素分析[J].重庆医科大学学报,2023,48(8):931-934.

Shan Xiongwei,Shidong Lü,Chen Liping,et al.Clinical characteristics and risk factors for prostate cancer with PSA≤20 ng/mL: a multicenter study[J].Journal of Chongqing Medical University,2023,48(8):931-934.
单雄威,吕世栋,陈丽萍,等.多中心研究PSA≤20 ng/mL前列腺癌临床特点及危险因素分析[J].重庆医科大学学报,2023,48(8):931-934. DOI： 10.13406/j.cnki.cyxb.003301.

Shan Xiongwei,Shidong Lü,Chen Liping,et al.Clinical characteristics and risk factors for prostate cancer with PSA≤20 ng/mL: a multicenter study[J].Journal of Chongqing Medical University,2023,48(8):931-934. DOI： 10.13406/j.cnki.cyxb.003301.

摘要

目的

探究前列腺特异抗原（prostate specific antigen，PSA）≤20 ng/mL前列腺癌患者骨转移临床特点及其与临床病理因素的相关性。

方法

回顾性分析2011年1月至2017年12月南方医院、珠江医院、南部战区总医院收治的初诊PSA≤20 ng/mL前列腺癌患者临床及病理资料。将患者分为骨转移组和非骨转移组，分析2组间年龄、PSA、结合PSA（complexed PSA，cPSA）、游离PSA（free PSA，fPSA）、Gleason评分（Gleason score，GS）、T分期及N分期的差异，以及这些因素与骨转移的相关性。进一步根据PSA、GS、T分期及N分期情况进行亚组分析：PSA≤10 ng/mL及PSA 10.01~20 ng/mL组、GS≤6组和GS≥7组、T

1~2

组和T

3~4

组、N

组及N

组，探究各亚组间骨转移特点。最后，采用单因素及多因素logistic回归分析评估骨转移危险因素。

结果

共237例PSA≤20 ng/mL前列腺癌患者，其中骨转移阳性42例（17.7%）。不同PSA组（

4 ng/mL组、≤10 ng/mL组及10.01~20 ng/mL组）前列腺癌骨转移率分别为7.5%、12.1%和24.8%。骨转移组与非转移组间PSA、cPSA、fPSA、GS、T分期及N分期差异均有统计学意义（

0.05），但2组间年龄差异无统计学意义（

0.05）。亚组分析结果显示：随着PSA及GS升高骨转移发生率也明显上升，T

3~4

和N

期患者更易发生骨转移（

=2.372，95%CI=1.148~4.901，

=0.020；

=6.458，95%CI=2.435~17.131，

0.001）。此外，logistic回归分析提示PSA、GS、T分期及N分期与PSA≤20 ng/mL前列腺癌骨转移密切相关，其中PSA、GS及N分期可作为骨转移的独

立危险因素（

0.05）。而年龄与骨转移的发生无相关性（

0.05）。

结论

PSA≤20 ng/mL前列腺癌患者中GS≥7、T

3~4

和N

期患者具有较强的侵袭性。PSA、GS及N分期可作为PSA≤20 ng/mL前列腺癌骨转移的独立危险因素。

Abstract

Objective

To explore the clinical characteristics of bone metastasis and its correlation with clinicopathological factors in patients with prostate cancer with prostate specific antigen（PSA） ≤20 ng/mL.

Methods

This study retrospectively analyzed the clinical and pathological data of patients who were newly diagnosed with prostate cancer with PSA ≤20 ng/mL in Nanfang Hospital，Zhujiang Hospital，and General Hospital of Southern Theater Command from January 2011 to December 2017. The patients were divided into two groups according to with or without bone metastasis. Differences in age，PSA，complexed PSA（cPSA），free PSA（fPSA），Gleason score（GS），and T and N stages were analyzed between the two groups，and the correlation of these factors with bone metastasis was analyzed. A further subgroup analysis was performed based on PSA levels（≤10 ng/mL and 10.01-20 ng/mL），GS（GS ≤ 6 and GS ≥ 7），T stages（T

1-2

and T

3-4

），and N stages（N

and N

） to explore the characteristics of bone metastasis between subgroups. Finally，univariate and multivariate logistic regression analyses were used to identify risk factors for bone metastasis.

Results

Of all 237 patients involved in this study，42（17.7%） patients showed bone metastases，and the incidence rates of bone metastasis in patients with PSA

4 ng/mL，patients with PSA≤10 ng/mL，and patients with PSA of 10.01-20 ng/mL were 7.5%，12.1%，and 24.8%，respectively. There were significant differences in PSA，cPSA，and fPSA levels，GS，and T and N stages between the patients with and without bone metastasis（

0.05）. There was no significant difference in age between the t

wo groups（

0.05）. The subgroup analysis further revealed that with the increases in PSA level and GS，the incidence of bone metastasis was consistently increased，and bone metastasis was more frequent in patients with stage T

3-4

and N

disease ［odds ratio（

）=2.372，95%CI=1.148-4.901，

=0.020；

=6.458，95%CI=2.435-17.131，

0.001］. logistic regression analyses showed that PSA level，GS，and T and N stages were closely related to bone metastasis in patients with prostate cancer with PSA ≤20 ng/mL，and PSA level，GS，and N stage were independent risk factors for bone metastasis（

0.05）. There was no significant association between age and bone metastasis（

0.05）.

Conclusion

More tumor aggressiveness is found in patients with GS ≥7 and stage T

3-4

and N

disease among patients with prostate cancer with PSA ≤20 ng/mL. PSA level，GS，and N stage are independent risk factors for bone metastasis in patients with prostate cancer with PSA ≤20 ng/mL.

关键词

Keywords

references

Zheng RS ， Zhang SW ， Zeng HM ， et al . Cancer incidence and mortality in China，2016 [J ] . J Natl Cancer Cent ， 2022 ， 2 （ 1 ）： 1 - 9 .

Shen P ， Zhao J ， Sun G ， et al . The roles of prostate-specific antigen（PSA）density，prostate volume，and their zone-adjusted derivatives in predicting prostate cancer in patients with PSA less than 20.0 ng/mL [J ] . Andrology ， 2017 ， 5 （ 3 ）： 548 - 555 .

Chang TH ， Lin WR ， Tsai WK ， et al . Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/mL [J ] . BMC Urol ， 2020 ， 20 （ 1 ）： 151 .

Lee SH ， Chung MS ， Park KK ， et al . Is it suitable to eliminate bone scan for prostate cancer patients with PSA≤20 ng/mL? [J ] . World J Urol ， 2012 ， 30 （ 2 ）： 265 - 269 .

Singh OP ， Yogi V ， Redhu P ， et al . Role of serum prostate-specific antigen as predictor for bone metastases in newly diagnosed prostate cancer [J ] . J Cancer Res Ther ， 2019 ， 15 （ Suppl ）： S39 - S41 .

Zaman MU ， Fatima N ， Sajjad Z . Metastasis on bone scan with low prostate specific antigen（≤20 ng/mL） and Gleason’s score（<8） in newly diagnosed Pakistani males with prostate cancer：should we follow Western guidelines? [J ] . Asian Pac J Cancer Prev ， 2011 ， 12 （ 6 ）： 1529 - 1532 .

Kosuda S ， Yoshimura I ， Aizawa T ， et al . Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan [J ] . Cancer ， 2002 ， 94 （ 4 ）： 964 - 972 .

Bruwer G ， Heyns CF ， Allen FJ . Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate [J ] . Eur Urol ， 1999 ， 35 （ 3 ）： 223 - 227 .

Ito K ， Kubota Y ， Suzuki K ， et al . Correlation of prostate-specific antigen before prostate cancer detection and clinicopathologic features：evaluation of mass screening populations [J ] . Urology ， 2000 ， 55 （ 5 ）： 705 - 709 .

Sanjaya IG ， Mochtar CA ， Umbas R . Correlation between low Gleason score and prostate specific antigen levels with incidence of bone metastases in prostate cancer patients：when to omit bone scans? [J ] . Asian Pac J Cancer Prev ， 2013 ， 14 （ 9 ）： 4973 - 4976 .

侯惠民，张亚群，李　欣，等 . 前列腺特异性抗原20 μg/L以下前列腺癌患者骨转移的相关因素分析 [J ] . 中华泌尿外科杂志， 2015 （ 6 ）： 439 - 441 .

Hou HM ， Zhang YQ ， Li X ， et al . Various factors of positive rate of bone scan in prostate cancer patients with prostate specific antigen less than 20 μg/L [J ] . Chinese Journal of Urology ， 2015 （ 6 ）： 439 - 441 .

Iwamoto H ， Izumi K ， Kadono Y ， et al . Prognosis of patients with prostate cancer and middle range prostate-specific antigen levels of 20-100 ng/mL [J ] . Int Braz J Urol ， 2019 ， 45 （ 1 ）： 61 - 67 .

Falchook AD ， Martin NE ， Basak R ， et al . Stage at presentation and survival outcomes of patients with Gleason 8-10 prostate cancer and low prostate-specific antigen [J ] . Urol Oncol ， 2016 ， 34 （ 3 ）： e19-119 .

Mahal BA ， Yang DD ， Wang NQ ， et al . Clinical and genomic characterization of low-prostate-specific antigen，high-grade prostate cancer [J ] . Eur Urol ， 2018 ， 74 （ 2 ）： 146 - 154 .

Nafie S ， Mellon JK ， Dormer JP ， et al . The role of transperineal template prostate biopsies in prostate cancer diagnosis in biopsy naïve men with PSA less than 20 ng/mL [J ] . Prostate Cancer Prostatic Dis ， 2014 ， 17 （ 2 ）： 170 - 173 .

Chen YH ， Lin Y ， Nie P ， et al . Associations of prostate-specific antigen，prostate carcinoma tissue gleason score，and androgen receptor expression with bone metastasis in patients with prostate carcinoma [J ] . Med Sci Monit ， 2017 ， 23 ： 1768 - 1774 .

Liu DY ， Kuai Y ， Zhu RH ， et al . Prognosis of prostate cancer and bone metastasis pattern of patients：a SEER-based study and a local hospital based study from China [J ] . Sci Rep ， 2020 ， 10 （ 1 ）： 9104 .

Lai MHY ， Luk WH ， Chan JCS . Predicting bone scan findings using sPSA in patients newly diagnosed of prostate cancer：feasibility in Asian population [J ] . Urol Oncol ， 2011 ， 29 （ 3 ）： 275 - 279 .

Tanaka N ， Fujimoto K ， Shinkai T ， et al . Bone scan can be spared in asymptomatic prostate cancer patients with PSA of ≤20 ng/mL and Gleason score of ≤6 at the initial stage of diagnosis [J ] . Jpn J Clin Oncol ， 2011 ， 41 （ 10 ）： 1209 - 1213 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Potential application of chymotrypsin-like proteasome activity as a biomarker for prostate cancer

TMEM9 promotes the proliferation and invasion of prostate cancer by affecting autophagy

Association of miR-296-5p，S-phase kinase-associated protein 2， and ribosomal protein L6 with the pathological features of prostate cancer and their influence on surgical prognosis

Deleted in liver cancer-1 inhibits the proliferation and invasion of enzalutamide-resistant prostate cancer cells via the Rho pathway

Application of nanoparticles in the treatment of prostate cancer

Related Author

Zeng Weiwei

Zhao Yongbin

Li Yugang

Liu Weichi

Zhou Yuchen

Liu Qilian

Zeng Jinghua

Su Shuai

Related Institution

Department of Urology，Integrated Hospital of Traditional Chinese Medicine，Southern Medical University

Department of Urology，The First Affiliated Hospital of Chongqing Medical University

Urology 2nd Ward, Xinxiang Central Hospital，The Fourth Clinical College of Xinxiang Medical College

Critical Care Medicine 1st Ward, Xinxiang Central Hospital，The Fourth Clinical College of Xinxiang Medical College

Department of Medical Genetics,Guizhou Provincial People’s Hospital

⁰